Terminated, withdrawn and suspended trials

clinicaltrialsObservedShowing 201–250 of 328 studies, most recently updated first

NCT	Title	Phase	Status	First posted	Lead sponsor	Why stopped (as posted)	Category
NCT00593554	Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies	Phase 2	terminated	Jan 15, 2008	Sherif S. Farag	Slow accrual	Enrollment / accrual
NCT02204020	Phase II Study of 5-azacytidine Maintenance After Transplant for AML or MDS(UPCI 13-165)	Phase 2	withdrawn	Jul 30, 2014	University of Pittsburgh	Lack of interest with investigators - no subjects enrolled	Enrollment / accrual
NCT00113646	Non-Myeloablative HLA-Mismatched Ex-Vivo T-cell Depleted Stem Cell Transplantation for…	Phase 2	terminated	Jun 10, 2005	Massachusetts General Hospital	Expiration of MEDI-507	Other (stated, no rule matched)
NCT00113828	Non-Myeloablative HLA-Matched Ex-Vivo T-cell Depleted Stem Cell Transplantation for…	Phase 2	terminated	Jun 13, 2005	Massachusetts General Hospital	Insufficient accrual	Enrollment / accrual
NCT02269579	Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine:…	Phase 2	withdrawn	Oct 21, 2014	Jazz Pharmaceuticals	not stated	Not stated
NCT02198482	Trial of Intensive Chemotherapy With or Without Volasertib in Patients With Newly…	Phase 2	terminated	Jul 23, 2014	University of Ulm	development program of study drug volasertib was stopped by Boehringer Ingelheim due to…	Drug supply
NCT00852709	Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated…(POE07-01)	Phase 1	terminated	Feb 27, 2009	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Lack of accrual	Enrollment / accrual
NCT01564277	Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies	Phase 2	terminated	Mar 27, 2012	Roswell Park Cancer Institute	low accrual	Enrollment / accrual
NCT01442714	Azacitidine + Lenalidomide Combo in the Elderly With Previously Treated AML & High-Risk…	Phase 2	terminated	Sep 28, 2011	Stanford University	Lack of efficacy - Inability to meet the primary response endpoint	Efficacy / futility
NCT00295880	Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating…	Phase 1 / Phase 2	terminated	Feb 24, 2006	Masonic Cancer Center, University of Minnesota	Time to engraftment would not be improved compared to historical controls.	Other (stated, no rule matched)
NCT00354172	Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood…	Phase 2	terminated	Jul 20, 2006	Masonic Cancer Center, University of Minnesota	Competing study was started.	Other (stated, no rule matched)
NCT00392782	Donor Stem Cell Transplant in Treating Patients With Myeloid Cancer or Other Disease	Phase 2	terminated	Oct 26, 2006	Masonic Cancer Center, University of Minnesota	not stated	Not stated
NCT00602446	Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell…	Phase 2	terminated	Jan 28, 2008	Masonic Cancer Center, University of Minnesota	Due to slow accrual of patients	Enrollment / accrual
NCT00818649	Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or…	Phase 2	terminated	Jan 8, 2009	Masonic Cancer Center, University of Minnesota	Met protocol stop rule \[i.e., extreme toxicity\]	Safety / toxicity
NCT00963872	Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and…	Phase 1 / Phase 2	terminated	Aug 24, 2009	Masonic Cancer Center, University of Minnesota	Lack of efficacy after interim analysis	Efficacy / futility
NCT00176839	Stem Cell Transplantation for Hematological Malignancies	Phase 2 / Phase 3	terminated	Sep 15, 2005	Masonic Cancer Center, University of Minnesota	Replaced by a different study	Other (stated, no rule matched)
NCT01207076	AHN-12 Biodistribution in Advanced Leukemia	Phase 1	terminated	Sep 22, 2010	Masonic Cancer Center, University of Minnesota	Slow accrual	Enrollment / accrual
NCT02765997	StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies	Phase 2	withdrawn	May 9, 2016	Masonic Cancer Center, University of Minnesota	IRB Disapproval	Other (stated, no rule matched)
NCT00376519	Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood…	Phase 1	terminated	Sep 15, 2006	Masonic Cancer Center, University of Minnesota	Slow accrual	Enrollment / accrual
NCT01163201	T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in…	Phase 1 / Phase 2	withdrawn	Jul 15, 2010	Masonic Cancer Center, University of Minnesota	Replaced by a new study	Other (stated, no rule matched)
NCT00290628	Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer	N/A	terminated	Feb 13, 2006	Masonic Cancer Center, University of Minnesota	Replaced with another study	Other (stated, no rule matched)
NCT00618696	Yttrium Y 90 Anti-CD45 Monoclonal Antibody AHN-12 in Treating Patients With Advanced…	Phase 1	terminated	Feb 20, 2008	Masonic Cancer Center, University of Minnesota	Replaced with another study	Other (stated, no rule matched)
NCT00725062	Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor…	Phase 1	terminated	Jul 30, 2008	Masonic Cancer Center, University of Minnesota	Slow accrual.	Enrollment / accrual
NCT02433483	Microtransplantation to Treat Refractory or Relapsed Hematologic Malignancies in Younger…	Phase 2	terminated	May 5, 2015	St. Jude Children's Research Hospital	The study was closed due to poor accrual and because of competing protocols.	Enrollment / accrual
NCT00281879	Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With…	Phase 2	terminated	Jan 25, 2006	OHSU Knight Cancer Institute	not stated	Not stated
NCT03138395	iCare3: Monitoring Circulating Cancer DNA After Chemotherapy in MDS and AML(iCare3)	—	withdrawn	May 3, 2017	University of Florida	Study design modified to collect specimens from a bank requiring a separate IRB-approved protocol.	Other (stated, no rule matched)
NCT01085656	A Phase I Clinical Trial of OXi4503 for Relapsed and Refractory AML and MDS	Phase 1	terminated	Mar 12, 2010	University of Florida	not stated	Not stated
NCT01034592	Pilot Lenalidomide in Adult Diamond-Blackfan Anemia Patients w/ RBC Transfusion-Dependent…	Phase 1	terminated	Dec 17, 2009	Jason Robert Gotlib	Poor accrual related to rarity of Diamond-Blackfan anemia (DBA)	Enrollment / accrual
NCT01076270	Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A…	N/A	terminated	Feb 26, 2010	Fred Hutchinson Cancer Center	Funding withdrawal	Funding
NCT00719849	Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological…	Phase 2	terminated	Jul 22, 2008	Fred Hutchinson Cancer Center	A new protocol was developed to replace this protocol in 2008, with removal of ATG and extension of…	Other (stated, no rule matched)
NCT00589602	T-Cell Depletion, Donor Hematopoietic Stem Cell Transplant (HSCT), and T-Cell Infusions…	Phase 2	terminated	Jan 9, 2008	The Cleveland Clinic	slow accrual	Enrollment / accrual
NCT02259348	Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following…	Phase 2	terminated	Oct 8, 2014	St. Jude Children's Research Hospital	Investigator's decision.	Investigator
NCT00450983	Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After…	Phase 2	terminated	Mar 22, 2007	Fred Hutchinson Cancer Center	not stated	Not stated
NCT00555048	Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in…	Phase 1 / Phase 2	terminated	Nov 7, 2007	Fred Hutchinson Cancer Center	Low accrual	Enrollment / accrual
NCT00997243	Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic…	Phase 2	terminated	Oct 19, 2009	Alison Walker	Drug no longer being supplied by sponsor	Other (stated, no rule matched)
NCT00324324	Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem…	Phase 3	terminated	May 11, 2006	OHSU Knight Cancer Institute	not stated	Not stated
NCT00900068	Blood Samples From Patients on a Clinical Trial to CINV During HSCT	—	terminated	May 12, 2009	OHSU Knight Cancer Institute	not stated	Not stated
NCT02564536	Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk…	Phase 1	withdrawn	Sep 30, 2015	Washington University School of Medicine	Lack of funding following full FDA clinical hold	Funding
NCT02200380	A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell…	Phase 2	terminated	Jul 25, 2014	Celldex Therapeutics	not stated	Not stated
NCT01607645	Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or…	Phase 2	terminated	May 30, 2012	Fred Hutchinson Cancer Center	The study was terminated early because there were other competing protocols.	Other (stated, no rule matched)
NCT01118013	Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or…	Phase 2	terminated	May 6, 2010	Alliance for Clinical Trials in Oncology	not stated	Not stated
NCT01749111	Comparison Between Cyclophosphamide and Combination of Methotrexate + Calcineurin…(CICLODECH)	Phase 3	terminated	Dec 13, 2012	Hospital Israelita Albert Einstein	Lack of accrual	Enrollment / accrual
NCT01621477	T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell…	Phase 2	terminated	Jun 18, 2012	St. Jude Children's Research Hospital	Study was terminated in August 2016 due to replacement by a new study.	Other (stated, no rule matched)
NCT00052598	Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or…	Phase 1 / Phase 2	terminated	Jan 27, 2003	Fred Hutchinson Cancer Center	not stated	Not stated
NCT00946283	Lactobacillus in Preventing Infection in Patients Undergoing a Donor Stem Cell Transplant…	N/A	terminated	Jul 24, 2009	Rutgers, The State University of New Jersey	slow accrual	Enrollment / accrual
NCT01709396	ED-TBI Followed By Allogeneic Stem Cell Transplantation For The Treatment Of Refractory…(ED-TBI)	Phase 2	suspended	Oct 18, 2012	Ottawa Hospital Research Institute	initial on hold due to space but now permanently suspended due to futility.	Efficacy / futility
NCT01520805	Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and…	Phase 2	withdrawn	Jan 30, 2012	Cornerstone Pharmaceuticals	not stated	Not stated
NCT00255684	Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and…	N/A	terminated	Nov 21, 2005	University of Rochester	low accrual	Enrollment / accrual
NCT02147873	Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL	Phase 2	terminated	May 28, 2014	TetraLogic Pharmaceuticals	Study terminated due to lack of efficacy	Efficacy / futility
NCT01652014	Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With…	Phase 2	withdrawn	Jul 27, 2012	University of Medicine and Dentistry of New Jersey	Funding unavailable	Funding

Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.

Data updated 23 days agoSource updated Apr 10, 2018source: clinicaltrials

Terminated, withdrawn and suspended studies

Stated reasons by category

Classification rules